169 related articles for article (PubMed ID: 31045816)
1. Pleural effusion as a substitute for tumor tissue in detecting EGFR/ALK mutations in non-small cell lung cancer: A systematic review and meta-analysis.
Pang C; Ma H; Qin J; Wang S; Wan C; Yang T; Shen Y; Wang D
Medicine (Baltimore); 2019 May; 98(18):e15450. PubMed ID: 31045816
[TBL] [Abstract][Full Text] [Related]
2. Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples.
Yao Y; Peng M; Shen Q; Hu Q; Gong H; Li Q; Zheng Z; Xu B; Li Y; Dong Y
Thorac Cancer; 2019 Feb; 10(2):193-202. PubMed ID: 30565433
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis.
Luo J; Shen L; Zheng D
Sci Rep; 2014 Sep; 4():6269. PubMed ID: 25201768
[TBL] [Abstract][Full Text] [Related]
4. CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.
Rizzo S; Petrella F; Buscarino V; De Maria F; Raimondi S; Barberis M; Fumagalli C; Spitaleri G; Rampinelli C; De Marinis F; Spaggiari L; Bellomi M
Eur Radiol; 2016 Jan; 26(1):32-42. PubMed ID: 25956936
[TBL] [Abstract][Full Text] [Related]
5. Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis.
Wang S; Ma P; Ma G; Lv Z; Wu F; Guo M; Li Y; Tan Q; Song S; Zhou E; Geng W; Duan Y; Li Y; Jin Y
Eur J Cancer; 2020 Jan; 124():1-14. PubMed ID: 31707279
[TBL] [Abstract][Full Text] [Related]
6. Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing.
Yeo CD; Kim JW; Kim KH; Ha JH; Rhee CK; Kim SJ; Kim YK; Park CK; Lee SH; Park MS; Yim HW
Lung Cancer; 2013 Aug; 81(2):207-12. PubMed ID: 23726527
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of mutation-specific antibodies for immunohistochemical detection of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis.
Chen Z; Liu HB; Yu CH; Wang Y; Wang L; Song Y
PLoS One; 2014; 9(9):e105940. PubMed ID: 25203004
[TBL] [Abstract][Full Text] [Related]
8. Is it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer?: A meta-analysis.
Liu Y; Xing Z; Zhan P; Liu H; Ye W; Lv T; Song Y
Medicine (Baltimore); 2016 Nov; 95(47):e5115. PubMed ID: 27893656
[TBL] [Abstract][Full Text] [Related]
9. High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients.
Kimura H; Fujiwara Y; Sone T; Kunitoh H; Tamura T; Kasahara K; Nishio K
Cancer Sci; 2006 Jul; 97(7):642-8. PubMed ID: 16827805
[TBL] [Abstract][Full Text] [Related]
10. Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC.
Chen X; Li K; Liu Z; Gai F; Zhu G; Lu S; Che N
Cancer Med; 2021 Apr; 10(7):2286-2292. PubMed ID: 33656807
[TBL] [Abstract][Full Text] [Related]
11. Insufficiency of peripheral blood as a substitute tissue for detecting EGFR mutations in lung cancer: a meta-analysis.
Li Z; Zhang Y; Bao W; Jiang C
Target Oncol; 2014 Dec; 9(4):381-8. PubMed ID: 24623059
[TBL] [Abstract][Full Text] [Related]
12. Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients.
Song Z; Wang W; Li M; Liu J; Zhang Y
Lung Cancer; 2019 Oct; 136():23-29. PubMed ID: 31421258
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the potential diagnostic role of anaplastic lymphoma kinase for inflammatory myofibroblastic tumours: a meta-analysis.
Wu S; Xu R; Wan Q; Zhu X; Zhang L; Jiang H; Zhao X
PLoS One; 2015; 10(4):e0125087. PubMed ID: 25910080
[TBL] [Abstract][Full Text] [Related]
14. Ventana immunohistochemistry assay for anaplastic lymphoma kinase gene rearrangement detection in patients with non-small cell lung cancer: A meta-analysis.
Zhiwei W; Yuan J; Yihui Y; Xin H; Jingtao C; Lei S; Yongjian D
Thorac Cancer; 2017 Sep; 8(5):471-476. PubMed ID: 28742247
[TBL] [Abstract][Full Text] [Related]
15. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies.
Liu X; Lu Y; Zhu G; Lei Y; Zheng L; Qin H; Tang C; Ellison G; McCormack R; Ji Q
J Clin Pathol; 2013 Dec; 66(12):1065-9. PubMed ID: 23888061
[TBL] [Abstract][Full Text] [Related]
16. Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study.
Liang H; Song X; Zhang Y; Zhang S; Li F; Fang J; Li J; Liang L; Nie L; Ma K; Zhang L; Wang X; Xu J; Wei Y; Wang J; Song Q; Tian G; Mu Y; Gu Y; Yang L; Sun P; Zhong W; Zhao J; Xu Y; Chen M; Wang M
Thorac Cancer; 2019 Jul; 10(7):1521-1532. PubMed ID: 31144459
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis.
Passiglia F; Rizzo S; Di Maio M; Galvano A; Badalamenti G; Listì A; Gulotta L; Castiglia M; Fulfaro F; Bazan V; Russo A
Sci Rep; 2018 Sep; 8(1):13379. PubMed ID: 30190486
[TBL] [Abstract][Full Text] [Related]
18. Detection of EGFR mutation in supernatant, cell pellets of pleural effusion and tumor tissues from non-small cell lung cancer patients by high resolution melting analysis and sequencing.
Lin J; Gu Y; Du R; Deng M; Lu Y; Ding Y
Int J Clin Exp Pathol; 2014; 7(12):8813-22. PubMed ID: 25674250
[TBL] [Abstract][Full Text] [Related]
19. Computed Tomography Imaging Characteristics of Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis.
Mendoza DP; Stowell J; Muzikansky A; Shepard JO; Shaw AT; Digumarthy SR
Clin Lung Cancer; 2019 Sep; 20(5):339-349. PubMed ID: 31164317
[TBL] [Abstract][Full Text] [Related]
20. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
